Announcements
- Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
- Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
- Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Alector to Participate in Upcoming Healthcare Conferences
- Alector Reports First Quarter 2024 Financial Results and Provides Business Update
- Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
- Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
- FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
More ▼
Key statistics
As of last trade Alector Inc (0Z2:STU) traded at 6.00, -24.05% below its 52-week high of 7.90, set on Jan 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.75 |
---|---|
High | 6.10 |
Low | 5.75 |
Bid | 6.00 |
Offer | 6.10 |
Previous close | 5.55 |
Average volume | 0.00 |
---|---|
Shares outstanding | 96.38m |
Free float | 87.73m |
P/E (TTM) | -- |
Market cap | 613.97m USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Jul 23 2024.
More ▼